US5422340A
Expired / Lapsed
US
⏱️ 0.0 years remaining
TGF-βformulation for inducing bone growth
Assignee: Individual
•
Filing: 1994-06-08
•
Granted: 1995-06-06
•
Expires: 2014-06-08
Abstract
Abstract A formulation suitable for inducing bone formation contains about 0.5 μg to about 5 mg of transforming growth factor-β and about 140 mg to about 50 g of tricalcium phosphate and excludes a bone morphogenetic cofactor. In another embodiment, the formulation contains about 0.5 μg to 5 mg transforming growth factor-β, about 140 mg to 50 g of tricalcium phosphate particles, and an amount of amylopectin ranging from about 01:1 to 1:1 amylopectin:tricalcium phosphate.
Inventors
- 👤 Arthur J. Ammann
- 👤 Steven L. Beck
- 👤 Tue H. Nguyen
- 👤 Boonsri Ongpipattanakul
- 👤 Christopher G. Rudman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:32
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/14; A61L27/22; A61L27/227; A61F; A61F2/00; A61F2/02; A61F2/28; A61K; A61K35/00; A61K35/12; A61K35/28; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1841; A61F2002/2817; A61F2/30; A61F2002/30001; A61F2002/30667; A61F2002/30677; A61L2430/00; A61L2430/02
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
28 words
A bone-inducing formulation consisting essentially of about 0.5 μg to about 5 mg of transforming growth factor-β and about 140 mg to about 50 g of tricalcium phosphate.
Claim 2
Dependent Claim
28 words
A bone-inducing formulation consisting essentially of about 0.5 μg to about 5 mg of transforming growth factor-β and about 140 mg to about 50 g of tricalcium phosphate.
Claim 3
Dependent Claim
11 words
The formulation of claim 1 wherein the tricalcium phosphate is particles.
Claim 4
Dependent Claim
13 words
The formulation of claim 2 wherein the particles are granules or a powder.
Claim 5
Dependent Claim
17 words
The formulation of claim 3 wherein the transforming growth factor-β is adsorbed on the granules or powder.
Claim 6
Dependent Claim
24 words
The formulation of claim 3 wherein the tricalcium phosphate is in the form of granules with a diameter of about 120 to 500 μm.
Claim 7
Dependent Claim
31 words
The formulation of claim 1 further comprising a polymer selected from amylopectin, gelatin, collagen, agarose, or a mixture of these polymers, in an amount effective to enhance consistency of the formulation.
Claim 8
Dependent Claim
12 words
The formulation of claim 6 wherein the polymer is lyophilized before use.
Claim 9
Dependent Claim
29 words
A bone-inducing formulation consisting essentially of about 0.5 μg to about 5 mg transforming growth factor-β adsorbed onto about 140 mg to about 50 g of tricalcium phosphate particles.
Claim 10
Dependent Claim
29 words
A bone-inducing formulation consisting essentially of about 0.5 μg to about 5 mg transforming growth factor-β adsorbed onto about 140 mg to about 50 g of tricalcium phosphate particles.
Claim 11
Dependent Claim
23 words
The formulation of claim 8 wherein about 1 μg to about 3 mg transforming growth factor-β is adsorbed onto the tricalcium phosphate particles.
Claim 12
Dependent Claim
15 words
The formulation of claim 8 wherein the size of the particles is about 120-500 μm.
Claim 13
Dependent Claim
15 words
The formulation of claim 10 wherein the size of the particles is about 125-250 μm.
Claim 14
Dependent Claim
40 words
A bone-inducing formulation consisting essentially of about 0.5 μg to about 5 mg transforming growth factor-β, about 140 mg to about 50 g tricalcium phosphate particles, and an amount of amylopectin that ranges from about 0.1:1 to 1:1 amylopectin:tricalcium phosphate.
Claim 15
Dependent Claim
40 words
A bone-inducing formulation consisting essentially of about 0.5 μg to about 5 mg transforming growth factor-β, about 140 mg to about 50 g tricalcium phosphate particles, and an amount of amylopectin that ranges from about 0.1:1 to 1:1 amylopectin:tricalcium phosphate.
Claim 16
Dependent Claim
18 words
The formulation of claim 12 wherein the amount of amylopectin ranges from about 0.25:1 to 0.5:1 amylopectin:tricalcium phosphate.
Claim 17
Dependent Claim
28 words
The formulation of claim 12 wherein the size of the particles is no less than about 75 μm and the ratio of tricalcium phosphate:amylopectin:TGF-β solution is about 1:0.5:0.5.
Claim 18
Dependent Claim
15 words
The formulation of claim 12 wherein the size of the particles is about 120-500 μm.
Claim 19
Independent Claim
57 words
A method of producing a bone-inducing formulation of transforming growth factor-β consisting essentially of admixing an effective amount of a liquid solution of the transforming growth factor-β with tricalcium phosphate granules for a sufficient period of time to adsorb the transforming growth factor-β onto the granules and contacting the resulting mixture with an effective amount of amylopectin.
Claim 20
Independent Claim
57 words
A method of producing a bone-inducing formulation of transforming growth factor-β consisting essentially of admixing an effective amount of a liquid solution of the transforming growth factor-β with tricalcium phosphate granules for a sufficient period of time to adsorb the transforming growth factor-β onto the granules and contacting the resulting mixture with an effective amount of amylopectin.
Claim 21
Dependent Claim
17 words
The method of claim 16 wherein the size of the granules is about 120 to 500 μm.
References Cited (Backward Citations)
US4278630A
Cited
EP0105014A2
Cited
GB2160528A
Cited
EP0169016A2
Cited
EP0193372A2
Cited
EP0193917A2
Cited
EP0200341A1
Cited
EP0213776A2
Cited
US4863902A
Cited
EP0243179A1
Cited
US4702734A
Cited
EP0261599A2
Cited
EP0267463A2
Cited
EP0267015A2
Cited
EP0268561A2
Cited
EP0269408A2
Cited
EP0308238A1
Cited
EP0312208A1
Cited
JPH01153647A
Cited
US4863732A
Cited
EP0326151A2
Cited
EP0335554A2
Cited
WO1990001955A1
Cited
EP0361896A2
Cited
WO1990004974A1
Cited
EP0375127A1
Cited
WO1990005755A1
Cited
WO1990009798A1
Cited
EP0393707A2
Cited
EP0395187A2
Cited
WO1990014359A1
Cited
US5158934A
Cited
WO1991003491A1
Cited
WO1993005823A1
Cited
EP0451390A1
Cited
WO1991019510A1
Cited
FR2667789A1
Cited
WO1992014481A1
Cited
EP0520237A2
Cited
EP0530804A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-06-05 | 1998-12-05 | 1999-06-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-06-05 | 2002-12-05 | 2003-06-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-06-05 | 2006-12-05 | 2007-06-06 | $7700.00 | Window Closed / Lapsed |